Itrevia HF-T QP boasts of latest defibrillator technology, closed loop stimulation and compatibility with a quadripolar lead, to help patients with heart failure conditions
BIOTRONIK, a manufacturer of cardiovascular medical technology, has announced that the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization defibrillator (CRT-D) devices. Itrevia HF-T QP includes the Closed Loop Stimulation (CLS) algorithm. Reportedly, only CLS is capable of appropriately adapting heart rate in response to physiological demands independent of body movements or respiratory rate.
Itrevia HF-T QP was recently approved by the Food and Drug Administration (FDA) for use with IS4 compatible left ventricular (LV) leads. The CRT-D device has a quadripolar header, which aims to offer more LV pacing options to optimise the CRT therapy.
“This device meets standards of other devices in the market and then adds CLS,” said Dr Alexander Mazur, MD, Clinical Associate Professor from the University of Iowa in Iowa City. “My patients with heart failure have greater risk of falling due to the incidence of orthostatic hypotension and it is beneficial to have the option of using CLS to treat them,” he added.
CLS, available in BIOTRONIK pacemakers since 2003, has been clinically proven to be more responsive in activities of daily living than accelerometers. Similar to BIOTRONIK’s Itrevia ICD and CRT-D series, released earlier this year, Itrevia HF-T QP includes additional therapies: morphology discrimination, atrial capture control, improved ATP optimisation and more LV pacing vectors. Combined, they claim to deliver more effective therapeutic options while reducing unnecessary shocks.
“The FDA has approved CLS as the only system to respond to acute mental stress and now this unique technology is available for more patients who can benefit from the expanded programming options of a quadripolar device. CLS and BIOTRONIK Home Monitoring are core technologies in our BIOTRONIK pacemakers and ICDs because we know, and have clinical evidence, that these technologies can improve the quality of patients’ lives,” said Marlou Janssen, President, BIOTRONIK.
Comments are closed.